Detalles de la búsqueda
1.
Randomized Phase II Study of Two Doses of Pixantrone in Patients with Metastatic Breast Cancer (NCCTG N1031, Alliance).
Oncologist
; 2022 Apr 21.
Artículo
en Inglés
| MEDLINE | ID: mdl-35445723
2.
Randomized Phase II Trial of Capecitabine and Lapatinib with or without IMC-A12 (Cituxumumab) in Patients with HER2-Positive Advanced Breast Cancer Previously Treated with Trastuzumab and Chemotherapy: NCCTG N0733 (Alliance).
Breast Cancer Res Treat
; 188(2): 477-487, 2021 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-33852121
3.
N083E (Alliance): long-term outcomes of patients treated in a pilot phase II study of docetaxel, carboplatin, trastuzumab, and lapatinib as adjuvant therapy for early-stage HER2-positive breast cancer.
Breast Cancer Res Treat
; 182(3): 613-622, 2020 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-32504284
4.
A Validated Nomogram to Predict Upstaging of Ductal Carcinoma in Situ to Invasive Disease.
Ann Surg Oncol
; 24(10): 2915-2924, 2017 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-28766196
5.
Identifying a subset of patients with DCIS who have a low likelihood of residual disease at surgical excision following a core needle biopsy.
J Surg Oncol
; 116(2): 213-219, 2017 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-28420032
6.
Low-Grade Malignant Proliferating Tricholemmal Tumor Associated With Occult Ductal Carcinoma In Situ of the Breast.
Am J Dermatopathol
; 38(10): e144-6, 2016 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-27149331
7.
Central pathology laboratory review of HER2 and ER in early breast cancer: an ALTTO trial [BIG 2-06/NCCTG N063D (Alliance)] ring study.
Breast Cancer Res Treat
; 143(3): 485-92, 2014 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-24395109
8.
Long-Term Ultrasound Twinkling Detectability and Safety of a Polymethyl Methacrylate Soft Tissue Marker Compared to Conventional Breast Biopsy Markers-A Preclinical Study in a Porcine Model.
Ultrasound Med Biol
; 50(7): 1001-1009, 2024 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-38575416
9.
Immunohistochemistry and fluorescence in situ hybridization assessment of HER2 in clinical trials of adjuvant therapy for breast cancer (NCCTG N9831, BCIRG 006, and BCIRG 005).
Breast Cancer Res Treat
; 138(1): 99-108, 2013 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-23420271
10.
Amyloidosis of the breast: predominantly AL type and over half have concurrent breast hematologic disorders.
Mod Pathol
; 26(2): 232-8, 2013 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-23018872
11.
Potential for the embryonic morphogen Nodal as a prognostic and predictive biomarker in breast cancer.
Breast Cancer Res
; 14(3): R75, 2012 May 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-22577960
12.
[Clinical diagnosis and treatment in an outbreak of Fasciola gigantica infection in Yunnan Province].
Zhongguo Ji Sheng Chong Xue Yu Ji Sheng Chong Bing Za Zhi
; 30(6): 455-9, 2012 Dec 30.
Artículo
en Zh
| MEDLINE | ID: mdl-23484257
13.
The breast tissue microbiome, stroma, immune cells and breast cancer.
Neoplasia
; 27: 100786, 2022 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-35366464
14.
Standardizing Pathologic Evaluation of Breast Carcinoma After Neoadjuvant Chemotherapy.
Arch Pathol Lab Med
; 147(5): 591-603, 2022 05 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-35976643
15.
Association of Residual Ductal Carcinoma In Situ With Breast Cancer Recurrence in the Neoadjuvant I-SPY2 Trial.
JAMA Surg
; 157(11): 1034-1041, 2022 11 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-36069821
16.
Detailed Reanalysis of 500 Breast Cancers With Equivocal HER2 Immunohistochemistry and Borderline ERBB2 Fluorescence In Situ Hybridization Results.
Am J Clin Pathol
; 156(5): 886-894, 2021 Oct 13.
Artículo
en Inglés
| MEDLINE | ID: mdl-33942843
17.
HER2 Testing for Breast Cancer in the Genomics Laboratory: A Sea Change for Fluorescence In Situ Hybridization.
Arch Pathol Lab Med
; 145(7): 883-886, 2021 07 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-33112955
18.
Assessment of Residual Cancer Burden and Event-Free Survival in Neoadjuvant Treatment for High-risk Breast Cancer: An Analysis of Data From the I-SPY2 Randomized Clinical Trial.
JAMA Oncol
; 7(11): 1654-1663, 2021 Nov 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-34529000
19.
Association of Event-Free and Distant Recurrence-Free Survival With Individual-Level Pathologic Complete Response in Neoadjuvant Treatment of Stages 2 and 3 Breast Cancer: Three-Year Follow-up Analysis for the I-SPY2 Adaptively Randomized Clinical Trial.
JAMA Oncol
; 6(9): 1355-1362, 2020 09 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-32701140
20.
Pan-TRK Immunohistochemistry: A Useful Diagnostic Adjunct For Secretory Carcinoma of the Breast.
Am J Surg Pathol
; 43(12): 1693-1700, 2019 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-31498178